TY - JOUR AU - Shang, J. AU - Hackett, M.L. AU - Harris, K. AU - Woodward, M. AU - Roberts, L.M. AU - Zhang, P. AU - Henry, A. TI - Mental health in the two years following hypertensive and normotensive pregnancy: The Postpartum, Physiology, Psychology and Paediatric follow-up (P4) cohort study JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 35 PY - 2024 SP - 43 EP - 50 PG - 8 SN - 2210-7789 DO - 10.1016/j.preghy.2023.12.008 UR - https://m2.mtmt.hu/api/publication/34727376 ID - 34727376 N1 - Discipline of Women's Health, School of Clinical Medicine, Faculty of Medicine, and Health, University of New South Wales, Sydney, Australia The George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia The George Institute for Global Health, School of Public Health, Imperial College London, United Kingdom Department of Women's and Children's Health, St George Hospital, Kogarah, NSW, Australia St George and Sutherland Clinical Campus, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia The George Institute for Global Health, China Export Date: 8 March 2024 Correspondence Address: Henry, A.; Discipline of Women's Health, Australia; email: amanda.henry@unsw.edu.au LA - English DB - MTMT ER - TY - JOUR AU - Thangaraj, Sai Sindhu AU - Gunlund, Tina-Signe Gissel AU - Stubbe, Jane AU - Palarasah, Yaseelan AU - Svenningsen, Per AU - Nielsen, Lise Hald AU - Ovesen, Per Glud AU - Jensen, Boye L. TI - Effect of short-term changes in salt intake on plasma cytokines in women with healthy and hypertensive pregnancies JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 35 PY - 2024 SP - 82 EP - 87 PG - 6 SN - 2210-7789 DO - 10.1016/j.preghy.2024.01.135 UR - https://m2.mtmt.hu/api/publication/34570274 ID - 34570274 LA - English DB - MTMT ER - TY - JOUR AU - Bhat, Adithya D. AU - Keasler, Paige M. AU - Kolluru, Lavanya AU - Dombrowski, Michael M. AU - Palanisamy, Arvind AU - Singh, Preet Mohinder TI - Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 34 PY - 2023 SP - 74 EP - 82 PG - 9 SN - 2210-7789 DO - 10.1016/j.preghy.2023.10.005 UR - https://m2.mtmt.hu/api/publication/34593044 ID - 34593044 AB - Background: Consensus on the relative efficacy of available antihypertensive agents used in pregnancy is lacking. Objective: To compare treatment success with antihypertensives and categorize by route of administration. Search strategy: MEDLINE, Embase, PubMed, Web of Science, Scopus, CINAHL, and clinicaltrials.gov were searched without date restriction.Data collection: Peer-reviewed randomized controlled trials (RCTs) comparing pharmacologic agents used to treat hypertension in parturients were included. Evaluated treatment groups included IV-labetalol (BBIV), IV-hydralazine (DIV), oral-nifedipine (CCBPO), sublingual nifedipine (CCBSL), IV-calcium channel blocker (nonspecific)(CCBIV), IV-nitroglycerine (NTG), epoprostenol infusion (PRO), IV-ketanserin (5HT2B), IV-diazoxide (BZO), oral-nifedipine + methyldopa (CCBAG), oral-methyl-dopa (AAG), and oral prazosin (ABPO). Analysis: Seventy-four studies (8324 patients) were eligible post PRISMA guidelines screening. Results were pooled using a Bayesian-approach for success of treatment (study defined target blood pressure), time to achieve target pressure, and neonatal intensive-care admissions.Results: Treatment success (primary outcome, 55 trials with 5518 patients) was analyzed. Surface under the cumulative ranking curve (SUCRA) was categorized for 13 drugs, CCBPO (0.84) followed by CCBSL (0.78) were most likely to be effective in achieving target blood pressure. After sub-grouping by presence/absence of pre-eclampsia, CCB-PO ranked highest for both [(0.82) vs. (0.77), respectively]. Serotonin antagonists (0.99) and nitroglycerin (0.88) ranked highest for time to target pressure. NICU admissions were lowest for alpha-2 agonists (0.89), followed by BB PO (0.82) and hydralazine IV (0.49).Conclusion: Oral calcium-channel blockers ranked highest for treatment success. Ketanserin achieved target blood pressure fastest, warranting additional research. The results should be interpreted with caution as SUCRA values may not indicate whether the differences between interventions have clinically meaningful effect sizes. LA - English DB - MTMT ER - TY - JOUR AU - Fitzgerald, Sarah AU - Deer, Evangeline AU - Hogg, James AU - Cornelius, Denise C. AU - Turner, Ty AU - Amaral, Lorena M. AU - Hoang, Ngoc AU - Edwards, Kristin AU - Herrock, Owen AU - Campbell, Nathan AU - Ibrahim, Tarek AU - LaMarca, Babbette TI - RUPP Th17s cause hypertension and mitochondrial dysfunction in the kidney and placenta during pregnancy JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 32 PY - 2023 SP - 50 EP - 56 PG - 7 SN - 2210-7789 DO - 10.1016/j.preghy.2023.04.002 UR - https://m2.mtmt.hu/api/publication/34302899 ID - 34302899 AB - Background: Preeclampsia (PE), new-onset hypertension (HTN), and organ dysfunction during the second half of pregnancy, is associated with an increase in inflammatory immune cells, including T helper 17 (Th17) cells. Studies have demonstrated that mitochondrial (mt) dysfunction is important in the pathogenesis of PE though causative factors have yet to be fully identified. Although Th17 cells, natural killer (NK) cells, and mt dysfunction contribute to HTN in the reduced uterine perfusion pressure (RUPP) rat model, the role of Th17 cells or IL-17 in mt dysfunction is unknown. Therefore, we hypothesize that RUPP stimulated Th17 cells cause HTN and mt dysfunction, which is alleviated with the blockade of IL-17. Methods: On gestational day 12 (GD12), RUPP Th17 cells were transferred into normal pregnant (NP) Sprague Dawley rats. A subset of NP + RUPPTh17 rats received IL-17RC (100 pg/day) on GD14-19. Blood pressure (MAP), NK cells, and mt function were measured on GD19 in all groups. Results: MAP increased in response to NP + RUPP Th17 compared to NP rats and was lowered with IL-17RC. Circulating and placental NK cells increased with NP + RUPP Th17 compared to NP and were lowered with IL-17RC. Renal mtROS increased in NP + RUPP Th17 compared to NP and was normalized with IL-17RC. Similar to PE women, placental mtROS decreased in NP + RUPP Th17 and was normalized with IL-17RC. Conclusion: Our results indicate that IL-17RC inhibition normalizes HTN, NK cell activation, and multi-organ mt dysfunction caused by Th17 cells stimulated in response to placental ischemia. LA - English DB - MTMT ER - TY - JOUR AU - Hessami, Kamran AU - Espinoza, Jimmy AU - Salmanian, Bahram AU - Castro, Eumenia AU - Shamshirsaz, Alireza A. AU - Shamshirsaz, Amir A. TI - Letter to editor - Placental basal plate myofibers and risk of hypertensive disorders of pregnancy JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 33 PY - 2023 SP - 32 EP - 33 PG - 2 SN - 2210-7789 DO - 10.1016/j.preghy.2023.07.001 UR - https://m2.mtmt.hu/api/publication/34237733 ID - 34237733 LA - English DB - MTMT ER - TY - JOUR AU - Blakey, Hannah AU - Sun, Ruyue AU - Xie, Long AU - Russell, Rebecca AU - Sarween, Nadia AU - Hodson, James AU - Hargitai, Beata AU - Marton, Tamás AU - A H Neil, Desley AU - Wong, Edwin AU - Sheerin, Neil S AU - Bramham, Kate AU - Harris, Claire L AU - Knox, Ellen AU - Drayson, Mark AU - Lipkin, Graham TI - Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 32 PY - 2023 SP - 43 EP - 49 PG - 7 SN - 2210-7789 DO - 10.1016/j.preghy.2023.04.001 UR - https://m2.mtmt.hu/api/publication/33767856 ID - 33767856 N1 - Renal Medicine Department, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom Research Development and Innovation, Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom National Renal Complement Therapeutics Centre, Newcastle, United Kingdom Department of Women and Children's Health, King's College London, London, United Kingdom Export Date: 17 February 2024 Correspondence Address: Blakey, H.; Renal Medicine, Mindelsohn Way, United Kingdom; email: hannahblakey@nhs.net Chemicals/CAS: complement, 9007-36-7; complement component C1q, 80295-33-6; complement component C3, 80295-41-6; complement component C3d, 80295-45-0; complement component C4, 80295-48-3, 80295-71-2; complement component C4d, 80295-52-9; properdin, 11016-39-0; Properdin Tradenames: Aperio eSlide Manager, Leica Biosystems, Germany; Cobas 6000, Hitachi; Dako Autostainer Link 48, Agilent, United States; QuickPlex SQ 120, Meso Scale, United States; Workbench software v15.0, Meso Scale, United States Manufacturers: Leica Biosystems, Germany; Agilent, United States; Hitachi; Hoffmann La Roche, United Kingdom; Meso Scale, United States Funding details: Kidney Research UK Funding text 1: We are grateful for the financial assistance provided by University Hospitals Birmingham Charities and the Queen Elizabeth Hospital Kidney Patient Association which allowed us to undertake this study. We gratefully acknowledge the contribution to this study made by the University of Birmingham's Human Biomaterials Resource Centre which has been supported through Birmingham Science City - Experimental Medicine Network of Excellence project. Funding text 2: We are grateful for the financial assistance provided by University Hospitals Birmingham Charities and the Queen Elizabeth Hospital Kidney Patient Association which allowed us to undertake this study. We gratefully acknowledge the contribution to this study made by the University of Birmingham’s Human Biomaterials Resource Centre which has been supported through Birmingham Science City - Experimental Medicine Network of Excellence project. Funding text 3: This study was supported by University Hospitals Birmingham Charities and Queen Elizabeth Hospital Kidney Patient Association. Prof Claire Harris receives funding from Kidney Research UK and Newcastle upon Tyne Hospitals NHS Charity. LA - English DB - MTMT ER - TY - JOUR AU - Alasztics, Bálint AU - Kovács, Árpád Ferenc AU - Pállinger, Éva AU - Szabó-Taylor, Katalin AU - Szabó, Gábor AU - Molvarec, Attila AU - Koller, Ákos AU - Rigó, János TI - Upregulation of exofacial peroxiredoxin-thioredoxin system of lymphocytes and monocytes in preeclampsia JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 31 PY - 2023 SP - 54 EP - 59 PG - 6 SN - 2210-7789 DO - 10.1016/j.preghy.2022.12.002 UR - https://m2.mtmt.hu/api/publication/33334444 ID - 33334444 LA - English DB - MTMT ER - TY - JOUR AU - Alasztics, B. AU - Kovács, Árpád Ferenc AU - Koller, A. AU - Pállinger, Éva AU - Rigo, J. TI - PO6_22. Exofacial expression of peroxiredoxin-1 on peripheral blood mononuclear cells in preeclampsia JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 33 PY - 2023 IS - Suppl.1 SP - e39 SN - 2210-7789 DO - 10.1016/j.preghy.2023.07.079 UR - https://m2.mtmt.hu/api/publication/34177601 ID - 34177601 LA - English DB - MTMT ER - TY - JOUR AU - Magee, Laura A. AU - Brown, Mark A. AU - Hall, David R. AU - Gupte, Sanjay AU - Hennessy, Annemarie AU - Karumanchi, S. Ananth AU - Kenny, Louise C. AU - McCarthy, Fergus AU - Myers, Jenny AU - Poon, Liona C. AU - Rana, Sarosh AU - Saito, Shigeru AU - Staff, Anne Cathrine AU - Tsigas, Eleni AU - von Dadelszen, Peter TI - The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice* JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 27 PY - 2022 SP - 148 EP - 169 PG - 22 SN - 2210-7789 DO - 10.1016/j.preghy.2021.09.008 UR - https://m2.mtmt.hu/api/publication/33510390 ID - 33510390 AB - All units managing hypertensive pregnant women should maintain and review uniform departmental management protocols and conduct regular audits of maternal & fetal outcomes. The cause(s) of pre-eclampsia and the optimal clinical management of the hypertensive disorders of pregnancy remain uncertain; therefore, we recommend that every hypertensive pregnant woman be offered an opportunity to participate in research, clinical trials and follow-up studies. LA - English DB - MTMT ER - TY - JOUR AU - Menkhorst, Ellen AU - Zhou, Wei AU - Santos, Leilani AU - Zhang, Jian-Guo AU - St-Pierre, Yves AU - Young, Morag J. AU - Dimitriadis, Evdokia TI - Galectin-7 dysregulates renin-angiotensin-aldosterone and NADPH oxide synthase pathways in preeclampsia JF - PREGNANCY HYPERTENSION J2 - PREGNANCY HYPERTENS VL - 30 PY - 2022 SP - 130 EP - 136 PG - 7 SN - 2210-7789 DO - 10.1016/j.preghy.2022.09.008 UR - https://m2.mtmt.hu/api/publication/33235420 ID - 33235420 N1 - Export Date: 21 January 2023 AB - Objectives: Preeclampsia is a life-threatening disorder of pregnancy unique to humans. Poor placentation in the first trimester of pregnancy is widely accepted to be an underlying cause of preeclampsia. Galectin-7 is abnormally elevated in chorionic villous samples and serum from women that subsequently develop pre-term preeclampsia. Administration of exogenous galectin-7 to pregnant mice causes preeclampsia-like features (hypertension, proteinuria), associated with dysregulation of the renin-angiotensin system (RAS). In this study investigated the mechanism by which galectin-7 induces alterations to tissue RAS homeostasis and ROS production. We hypothesized that galectin-7 induces alterations in the production of either placental RAS or NADPH oxidases (or both) to drive the dysregulated RAS and ROS production seen in preeclampsia.Study Design: Mated female mice (n = 5-6/group) received single (embryonic day [E]12/13) or multiple (E8-12) subcutaneous injections of 400 mu g/kg/day galectin-7 or vehicle control and killed on E13 or E18. Human first trimester placental villous and decidual tissue (n = 11) was cultured under 8 % oxygen with 1 mu g/mL galectin-7 or vehicle control for 16 h.Results: Galectin-7 administration to pregnant mice impaired placental labyrinth formation, suppressed circulating aldosterone and altered placental RAS (Agt, Renin) and NADPH oxidase (Cyba, Cybb and Icam1) mRNA expression. In vitro, galectin-7 regulated human placental villous RAS (AGT) and NADPH oxidase (CYBA, ICAM1 and VCAM1) mRNA expression.Conclusions: Overall, galectin-7 likely drives hypertension in preeclampsia via its direct regulation of multiple pathways associated with preeclampsia in the placenta. Galectin-7 may therefore be a therapeutic target to improve placental function and prevent preeclampsia. LA - English DB - MTMT ER -